Project-Team Monc
Team, Visitors, External Collaborators
Overall Objectives
Objectives
General strategy
Research Program
Introduction
Axis 1: Tumor modeling for patient-specific simulations
Axis 2: Bio-physical modeling for personalized therapies
Axis 3: Quantitative cancer modeling for biological and preclinical studies
Application Domains
Tumor growth monitoring and therapeutic evaluation
Biophysical therapies
Experimental research in oncology
Highlights of the Year
New Software and Platforms
Nenuphar
papriK
NENUCORE
metamats_burden
metamats_core
IRENA
metamats_size
Carcinom
Platforms
New Results
Mathematical Modeling of the Proliferation Gradient in MultiCellular Tumor Spheroids
Viscoelastic modeling of the fusion of multicellular tumor spheroids in growth phase
Mathematical analysis and 2-scale convergence of a heterogeneous microscopic bidomain model
Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy
T2‐based MRI Delta‐radiomics improve response prediction in soft‐tissue sarcomas treated by neoadjuvant chemotherapy
Revisiting bevacizumab + cytotoxics scheduling using mathematical modeling: proof of concept study in experimental non-small cell lung carcinoma
Bilateral Contracts and Grants with Industry
Bilateral Contracts with Industry
Partnerships and Cooperations
National Initiatives
European Initiatives
International Initiatives
International Research Visitors
Dissemination
Promoting Scientific Activities
Teaching - Supervision - Juries
Popularization
Bibliography
Major publications
Publications of the year
Inria
|
Raweb 2018
|
Presentation of the Project-Team MONC
|
MONC Web Site
PDF
e-Pub
Previous |
Home
| Next
Section: Bilateral Contracts and Grants with Industry
Bilateral Contracts with Industry
Research contract between the pharmaceutical company Roche and the MONC team.
Previous |
Home
| Next